Astellas Pharma Inc
F:YPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
China BlueChemical Ltd
HKEX:3983
|
CN |
|
Contemporary Amperex Technology Co Ltd
SZSE:300750
|
CN |
|
S
|
Shh Resources Holdings Bhd
KLSE:SHH
|
MY |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (10.6), the stock would be worth €18.38 (35% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.9 | €13.6 |
0%
|
| 3-Year Average | 10.6 | €18.38 |
+35%
|
| 5-Year Average | 11.1 | €19.13 |
+41%
|
| Industry Average | 10.6 | €18.33 |
+35%
|
| Country Average | 8.7 | €14.97 |
+10%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
€4.6T
|
/ |
Jan 2026
¥586.5B
|
= |
|
|
€4.6T
|
/ |
Mar 2026
¥611.5B
|
= |
|
|
€4.6T
|
/ |
Mar 2027
¥681.9B
|
= |
|
|
€4.6T
|
/ |
Mar 2028
¥639.1B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Astellas Pharma Inc
F:YPHA
|
4.6T EUR | 7.9 | 14.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 28.7 | 42.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD | 17.2 | 26.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP | 16.8 | 30.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.5 | 19.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF | 12.6 | 20.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD | 10 | 16.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.3 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD | 7.7 | 20.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD | 7.2 | 17.2 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 6.7 |
| Median | 8.7 |
| 70th Percentile | 12.2 |
| Max | 214 699 781.2 |
Other Multiples
Astellas Pharma Inc
Glance View
Astellas Pharma Inc., a beacon in Japan's pharmaceutical landscape, weaves its narrative from a rich tapestry of innovation and strategic acumen. Born from the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas quickly established itself as a global powerhouse based in Tokyo. The company operates primarily by investing heavily in R&D to drive breakthroughs in life sciences, particularly focusing on therapeutic areas like oncology, urology, immunology, and transplant-related therapies. Through these focal points, Astellas channels its resources to cultivate novel treatments that address unmet medical needs, thereby enhancing the quality of life for patients worldwide. The financial architecture of Astellas Pharma is underpinned by its strategic prowess in expanding its product pipelines and leveraging partnerships to amplify its reach. Revenue generation primarily hinges on its robust product offerings, spearheaded by successful medications such as XTANDI for prostate cancer and Prograf, which aids in organ transplantation outcomes. This diversified product portfolio is complemented by an astute approach to global market penetration, where Astellas not only markets these pharmaceuticals but also strategically collaborates with biotech firms and research institutions to harness cutting-edge technologies. This business model not only propels profitability but also ensures that Astellas remains at the forefront of medical innovation, positioning itself as a pivotal entity within the pharmaceutical industry.
